NEWS
Studies Support Expanded Role for Lenalidomide in Treating Multiple Myeloma
Maintenance therapy with the drug lenalidomide (Revlimid) substantially lengthens the time patients with multiple myeloma live without their cancers progressing, according to the results of three randomized placebo-controlled clinical trials published May 10 in the New England Journal of Medicine. Overall survival was also improved in one of the trials, but according to several researchers, that conclusion is less definitive.
The results also showed that lenalidomide maintenance therapy carries an increased risk of second primary cancers. Read more > >
Low-Dose Radioactive Iodine Destroys Thyroid Tissue Left after Surgery
Whether low-risk patients should receive radioactive iodine at all remains a questionSequencing Study Identifies Gene that May Contribute to Melanoma
PREX2 gene, chromosomal rearrangements may play important roles in the diseaseExperimental Gene Therapy Protects Normal Cells from Toxic Effects of Chemotherapy
Protecting normal blood cells allows aggressive treatment for brain tumor patientsAlso in the News: Sunburn and Indoor Tanning Still Common
A MESSAGE TO READERS
Coverage of ASCO Annual Meeting
The American Society of Clinical Oncology's 48th Annual Meeting will take place June 1–5 in Chicago, IL. Click on the tile to learn more about sessions with NCI staff and activities at the NCI exhibit booth. Look for highlights from the meeting in the May 29 and June 12 issues of the NCI Cancer Bulletin.
IN DEPTH
Unearthing Clues to Cancer Risk in the Aging Genome
Some healthy individuals have unexpected chromosome anomalies, which appear to increase with age
Complex Immune-Based Cancer Treatment Shows Signs of Progress
Genetically engineered T cells are being studied for a variety of cancers, but hurdles to clinical use remain
"Rewiring" Cells to Treat an Aggressive Breast Cancer
Study of signaling networks in cancer cells reveals potential treatment
Featured Clinical Trial: Experimental Antibody for Treatment-Resistant Liver Cancer
Will new biological agent prolong time to disease progression in patients who didn't benefit from sorafenib?
UPDATES
NIH Update
- NIH, Industry, and Researchers Collaborate to Find New Uses for Existing Drugs
Notes
- NCI's Ann O'Mara Receives American Pain Society Award
- Cancer Classroom Webinar: The Social Determinants of Health
- What You Need to Know About Cancer Booklets Updated
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
